Psyched Wellness (CSE:PSYC, OTCQB:PSYCF) Ltd, a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, has announced that the initial pilot production run of its first-to-market AME-1 product Calm is scheduled for July 7, 2022.
Calm, an extract which harnesses the Amanita Muscaria mushroom's ability to de-stress and facilitate restful sleep, will be available over-the-counter and without a prescription, making it the first legal Amanita Muscaria mushroom product to be sold in North America.
"The final formulation for Calm underwent many calibrations over the last few months. We feel an inherent responsibility to bring the absolute best product to market,” Psyched Wellness chief commercial officer Matthew Singh said in a statement.
READ: Psyched Wellness announces launch of first online store
“Each calibration that improved our offering motivated the R&D, Operations, and Production teams to continue reformulating and optimizing until Calm reached its current form. It was important for our team to stay focused and not rush what is arguably the most integral part of product development. Our entire company is excited to share this version of Calm with the world, starting with a release in the United States,” he added.
The inaugural production of Calm signals that the company is on track to transition from an R&D organization to a full-scale commercial consumer packaged goods (CPG) entity capable of generating revenue, Psyched Wellness said.
Assuming a successful pilot production, the company said it plans to produce a craft number of units that will be used to test all flavor profiles and shared with opinion leaders. It added that updates on the pilot run can be expected 24 to 48 hours after production.
Psyched Wellness is a Canadian-based health supplements company dedicated to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The company is in the process of developing a line of Amanita Muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
Contact the author at jon.hopkins@proactiveinvestors.com